Literature DB >> 15580462

[Acute central nervous symptoms in oncologic patients].

K Orlopp1, I G H Schmidt-Wolf, H Urbach, U Schlegel.   

Abstract

Oncologic patients may suffer from acute central nervous system disorders either related to the disease itself or to its therapy. These disorders may present as a disturbance of consciousness, as mental changes, as focal neurological signs, as epileptic seizures or as a combination of these. Symptoms may be caused by cerebral metastases, hemorrhage, ischemia or infectious complication, by metabolic changes or by treatment sequealae. This article will focus on clinical presentation, diagnostic workup and possible therapy or prophylaxis of these complications.

Entities:  

Mesh:

Year:  2005        PMID: 15580462     DOI: 10.1007/s00108-004-1315-3

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  22 in total

1.  Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients.

Authors:  F Graus; F Keime-Guibert; R Reñe; B Benyahia; T Ribalta; C Ascaso; G Escaramis; J Y Delattre
Journal:  Brain       Date:  2001-06       Impact factor: 13.501

2.  Anti-Hu--associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients.

Authors:  J Dalmau; F Graus; M K Rosenblum; J B Posner
Journal:  Medicine (Baltimore)       Date:  1992-03       Impact factor: 1.889

3.  Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia: analysis of Cancer and Leukemia Group B 9013.

Authors:  M L Hensley; B Peterson; R T Silver; R A Larson; C A Schiffer; T P Szatrowski
Journal:  J Clin Oncol       Date:  2000-03       Impact factor: 44.544

4.  Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor.

Authors:  F Keime-Guibert; F Graus; P Broët; R Reñé; J L Molinuevo; C Ascaso; J Y Delattre
Journal:  Neurology       Date:  1999-11-10       Impact factor: 9.910

5.  Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone.

Authors:  F Keime-Guibert; F Graus; A Fleury; R René; J Honnorat; P Broet; J Y Delattre
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

Review 6.  Cisplatin-induced encephalopathy and seizures.

Authors:  N Steeghs; F E de Jongh; P A E Sillevis Smitt; M J van den Bent
Journal:  Anticancer Drugs       Date:  2003-07       Impact factor: 2.248

Review 7.  Long-term complications of chemotherapy for germ cell tumours.

Authors:  Uzair B Chaudhary; Jason R Haldas
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.

Authors:  Richard A Drachtman; Peter D Cole; Carla B Golden; S Jill James; Stepan Melnyk; Jospeh Aisner; Barton A Kamen
Journal:  Pediatr Hematol Oncol       Date:  2002 Jul-Aug       Impact factor: 1.969

Review 9.  Coagulation abnormalities in malignancy: a review.

Authors:  R L Bick
Journal:  Semin Thromb Hemost       Date:  1992       Impact factor: 4.180

10.  Acute promyelocytic leukemia in 57 previously untreated patients.

Authors:  C Cordonnier; J P Vernant; B Brun; M G Heilmann; M Kuentz; P Bierling; J P Farcet; M Rodet; N Duedari; M Imbert
Journal:  Cancer       Date:  1985-01-01       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.